(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 12.89% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Ani Pharmaceuticals's revenue in 2025 is $614,376,000.On average, 7 Wall Street analysts forecast ANIP's revenue for 2025 to be $16,733,552,093, with the lowest ANIP revenue forecast at $16,595,769,322, and the highest ANIP revenue forecast at $16,830,923,230. On average, 7 Wall Street analysts forecast ANIP's revenue for 2026 to be $18,059,907,228, with the lowest ANIP revenue forecast at $17,299,053,695, and the highest ANIP revenue forecast at $18,899,406,680.
In 2027, ANIP is forecast to generate $19,205,193,854 in revenue, with the lowest revenue forecast at $17,841,214,094 and the highest revenue forecast at $20,641,287,480.